This is Huge News For Eli Lilly Investors

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide-1 (GLP-1) agonists, Mounjaro and Zepbound, are just two of the company's blockbuster drugs helping pave the way in diabetes and obesity care, respectively.Lilly's success in the weight loss realm isn't without hiccups, though.  The company has experienced turbulence in meeting rising demand for its GLP-1 medications. As a result, some patients are opting for lower-cost alternatives, that potentially could stifle Lilly's near-term growth.Nevertheless, I see a couple of important progress updates that could serve as nice tailwinds for Lilly in the long run. Below, I'll detail some moves the company is making and explain how these investments should help it supercharge its momentum.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool